Home Women’s Cancer Women with Angelina Jolie gene could be monitored for breast cancer risk – study

Women with Angelina Jolie gene could be monitored for breast cancer risk – study

by admin
0 comment

Studies suggest that women with the “Angelina Jolie gene” may be able to closely monitor their risk of breast cancer and avoid radical surgery.

The study found that women with a hereditary defective BRCA1 gene could take a drug called mifepristone to slow down the turnover of cells that pose a risk for triple-negative breast cancer. I did. Mifepristone acts by blocking the effects of progesterone and is used in medical abortions where pills are taken to end pregnancy.

By the age of 80, women with a defect in the BRCA1 gene have a 65-79% lifetime risk of breast cancer and a 36-53% risk of ovarian cancer, according to the NHS. A new study published at Genome Medicine is the European Research Council and the Gynecologic Cancer Charity Eve Appeal.

During the study, researchers led by Professor Martin Widschwender of the University of Innsbruck (LFUI) and University College London (UCL) “signed” (DNA methyl) markers on DNA that help show and monitor the risk of breast cancer. I found it. The researchers used the WID-Breast 29 test on samples taken from the breasts of women who were all taking mifepristone at low doses, with or without BRCA mutations.

All women without the gene were found to have low levels of progesterone (which is thought to help promote breast cancer at high levels) and cell turnover. This effect was also seen in about three-quarters of women with BRCA mutations.

Experts hope that these women with defective genes may be targeted by mifepristone to delay the risk of developing breast cancer and keep progesterone levels low. Similarly, this can mean that the need for mastectomy can be delayed or potentially avoided. Currently, women with a BRCA1 gene deficiency can choose to have both breasts removed to reduce their risk of cancer. This is Jolie’s choice.

Professor Widschwendter said: A study published today assesses daily progesterone levels throughout the menstrual cycle and shows that progesterone levels are significantly higher in BRCA1 mutant carriers. Having this mutation increases the risk of developing breast cancer with a poor prognosis.

“Most importantly, we have shown that drugs that neutralize progesterone activity can reduce the changes in cells that promote the development of cancer in normal breast tissue in young women. These findings are for breast cancer prevention. We are really excited about the potential for improvement. “

Athena Lamnisos, Chief Executive Officer of Eve Appeal, said: And while it applies to the diagnosis of some breast cancers, it does not apply to the rarer and more aggressive forms of breast cancer. These new discoveries have the potential to become game changers, although they are currently brutal diagnoses. “

Dr. Kotryna Temcinaite, Senior Research and Communications Manager at Breast Cancer Now, said: These exciting early study results suggest that drugs that neutralize progesterone activity may be a potential risk-reducing treatment for women with altered BRCA genes.

“Women with altered BRCA1 genes are at increased risk of triple-negative breast cancer, which is difficult to treat, so it would be very beneficial to be able to stop the development of breast cancer. Establish how feasible this treatment is. We look forward to seeing further research to better understand the potential side effects. “

You may also like

Leave a Comment

Blue__white_and_green_Medical_care_logo-removebg-preview (1) (2)

HealCancer is the best newspaper and magazine website with tons of news articles and information about cancer and its facts and symptoms and research as well. This website is dedicated to spread awareness about the illness and help better understand and deal with it, visit our home page for more news .

Editors' Picks

Latest Posts

HEALCANCER – All Right Reserved.